A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Erythrocin Side Effects, and Drug Interactions - Erythromycin Stearate
Erythrocin Side Effects, and Drug Interactions - Erythromycin Stearate
SIDE EFFECTS
The most frequent side
effects of oral erythromycin
preparations are gastrointestinal and are dose-related. They include
nausea, vomiting,
abdominal pain, diarrhea
and anorexia. Symptoms of hepatic
dysfunction and/or
abnormal liver function
test results may occur
(see WARNINGS.) Pseudomembranous
colitis has been rarely
reported in association
with erythromycin therapy.
There have been isolated reports of transient
central nervous
system side effects including confusion,
hallucinations, seizures, and vertigo; however, a cause
and effect relationship
has not been established.
Occasional case reports
of cardiac arrhythmias
such as ventricular
tachycardia have been documented in patients receiving erythromycin
therapy. There have been isolated reports of other cardiovascular
symptoms such as chest
pain, dizziness, and
palpitations; however, a cause
and effect relationship
has not been established.
Allergic reactions ranging from urticaria
and mild skin eruptions
to anaphylaxis have occurred.
There have been isolated reports of reversible
hearing loss
occurring chiefly in patients with renal
insufficiency
and in patients receiving high doses of erythromycin.
DRUG INTERACTIONS
Erythromycin use in patients who are receiving high doses of theophylline
may be associated with an increase in serum
theophylline levels
and potential theophylline toxicity. In
case of theophylline
toxicity and/or elevated
serum theophylline
levels, the dose of theophylline
should be reduced while the patient
is receiving concomitant
erythromycin therapy.
Concomitant administration
of erythromycin
and digoxin has been
reported to result in elevated digoxin
serum levels.
There have been reports of increased anticoagulant
effects when erythromycin and oral
anticoagulants were used concomitantly.
Concurrent use of erythromycin
and ergotamine or
dihydroergotamine has been associated in some patients with acute
ergot toxicity
characterized by severe peripheral
vasospasm and dysesthesia.
Erythromycin has been reported to decrease the clearance
of triazolam and thus may increase the pharmacologic effect
of triazolam.
The use of erythromycin
in patients concurrently taking drugs metabolized by the cytochrome
P450 system may be associated
with elevations in serum erythromycin with carbamazepine, cyclosporine,
hexobarbital and phenytoin. Serum concentrations of drugs metabolized
by the cytochrome
P450 system should be monitored closely in patients concurrently
receiving erythromycin.
Troleandomycin significantly alters the metabolism
of terfenadine when taken concomitantly; therefore, observe caution
when erythromycin
and terfenadine are used concurrently.
Patients receiving concomitant
lovastatin and erythromycin
should be carefully monitored; cases of rhabdomyolysis
have been reported in seriously ill patients.
top
